ABIVAX Abstract On Obefazimod Phase 2B Results Selected For Moderated Poster Presentation At UEG Week 2022

Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance

Related Keywords

Austria ,Leuven ,Region Flamande ,Belgium ,United States ,Vienna ,Wien ,Paris ,France General ,France ,Regina Jehle ,Enregistrement Universel ,Ghislaine Gasparetto ,Jeanene Timberlake ,Ligia Vela Reid ,Anne Hennecke ,Severine Vermeire ,Gastroenterol Hepatol ,Mc Services ,University Hospitals Leuven ,Rooney Partners ,Relations Investors Europe ,Euronext ,Euronext Paris ,United European Gastroenterology ,Science Lounge ,Virtual Poster ,Inflammatory Bowel Diseases ,Poster Session ,Lancet Gastroenterology ,Mayo Score ,Review Board ,Truffle Capital ,French Autorit ,Des March ,Impact Factor ,Citation Reports ,Lancet Gastroenterol Hepatol ,Abivax ,Abstract ,Obefazimod ,Hase ,Results ,Elected ,Moderated ,Poster ,Presentation ,Eek ,022 ,